Experimental therapies for multiple sclerosis: current status
Donald E. Goodkin, MDAddress reprint requests to D.E.G., The Mellen Center for Multiple Sclerosis Treatment and Research, The Cleveland Clinic Foundation, 9500 Euclid Avenue (U-10), Cleveland, OH 44195.
Richard M. Ransohoff, MD
Richard A. Rudick, MD
Multiple sclerosis is the most common cause of non traumatic disability affecting young adults in the United States. Its etiology remains unclear, but evidence points to alteration of normal immune system function in the pathogenesis of this illness. This article reviews the results of clinical trials of experimental therapeutic agents in multiple sclerosis. The background and action of each treatment are described, and the clinical experience with each agent is reviewed. Obstacles to evaluating the effectiveness of treatment methods in MS and challenges to the design of future clinical trials and the interpretation of trial outcomes are discussed.